373 Bladder Cancer Clinical Trials Recruiting Now (July 2026): FGFR, TAR-210 MoonRISe, Nectin-4, TROP2 ADCs, Enfortumab Vedotin, Erdafitinib

Last updated: July 1, 2026

Current Clinical Trial Landscape

Recruiting Trials by Disease Stage

Non-Muscle-Invasive Bladder Cancer (NMIBC)

BCG is standard but many patients are BCG-unresponsive. New intravesical and systemic options are being tested:

• BCG alternatives / additions (gene therapy, intravesical):
  • NCT06510374 - ABLE-32: nadofaragene firadenovec (gene therapy) vs observation in intermediate-risk NMIBC (Phase 3, Ferring)
  • NCT06545955 - ABLE-22: nadofaragene firadenovec ± BCG in BCG-naïve high-risk NMIBC (Phase 3, Ferring)
• FGFR-targeted intravesical delivery (TAR-210 / erdafitinib intravesical):
  • NCT06319820 - MoonRISe-1: TAR-210 (erdafitinib intravesical delivery system) vs single-agent intravesical chemotherapy in intermediate-risk NMIBC with FGFR alterations (Phase 3, Janssen). First Phase 3 of an intravesical FGFR-targeted therapy.
  • NCT06919965 - MoonRISe-3: TAR-210 vs intravesical chemotherapy in patients with intermediate-risk NMIBC (Phase 3, Janssen). Companion study to MoonRISe-1 with broader NMIBC population.

Muscle-Invasive Bladder Cancer (MIBC)

Neoadjuvant and perioperative immunotherapy trials — testing whether IO before/after surgery improves outcomes:

• Neoadjuvant / perioperative:
  • NCT06960577 - Perioperative durvalumab + neoadjuvant ddMVAC or gemcitabine/cisplatin in MIBC (Phase 3, AstraZeneca). Extends the NIAGARA-style perioperative durvalumab regimen with chemotherapy backbone choice.
  • NCT06879145 - SHR-A2102 (ADC) + tislelizumab in MIBC (Phase 2/3, Suzhou Suncadia)
  • NCT07067749 - TEMPO-MIBC: MRI-guided treatment optimization for MIBC (Phase 3)

Locally Advanced or Metastatic Urothelial Carcinoma

Enfortumab vedotin + pembrolizumab is becoming standard first-line. New ADCs and combinations are being tested:

• Novel ADCs (Nectin-4, TROP2, B7-H3, HER2-expressing):
  • NCT07129993 - Datopotamab deruxtecan (TROP2 ADC) + carboplatin or cisplatin vs gemcitabine/cisplatin in 1L advanced urothelial carcinoma (Phase 2/3, Daiichi Sankyo). First Phase 2/3 of a TROP2 ADC in 1L urothelial.
  • NCT07419295 - Sacituzumab tirumotecan (Sac-TMT, MK-2870) for urothelial carcinoma (Phase 3, Merck) — another TROP2 ADC
  • NCT06857175 - BL-B01D1 (EGFR×HER3 bispecific ADC) vs chemotherapy in recurrent/metastatic urothelial carcinoma (Phase 3, Sichuan Baili)
  • NCT06738251 - SHR-A2102 (HER3 ADC) vs investigator's choice in advanced urothelial carcinoma (Phase 3, Shanghai Hengrui)
  • NCT06196736 - 9MW2821 (Nectin-4 ADC) vs chemotherapy in previously treated urothelial carcinoma (Phase 3, Mabwell)
• IO combinations:
  • NCT06524544 - Pembrolizumab + sacituzumab govitecan vs standard in metastatic UC (Phase 3) — investigational; the Trodelvy urothelial FDA indication was voluntarily withdrawn Apr 2025 after TROPiCS-04 missed its primary OS endpoint
• FGFR-targeted (FGFR2/3 alterations):
  • NCT07218380 - Vepugratinib (LY3866288, Lilly next-gen FGFR inhibitor) in urothelial cancer (Phase 3, activated 2026-06-24 — challenges erdafitinib as the FGFR-mutated 2L+ standard in the ~20% FGFR2/3-altered urothelial subset)

Upper Tract Urothelial Carcinoma (UTUC)

A distinct subtype affecting the renal pelvis and ureter — fewer trials but growing interest:

• • NCT04574960 - NAUTICAL: Neoadjuvant treatment for upper tract invasive cancer (Phase 3)
  • NCT04865939 - Gemcitabine vs water irrigation in upper tract urothelial carcinoma (Phase 3)

Showing selected notable trials. View all 373 recruiting interventional trials on ClinicalTrials.gov.

Frequently Asked Questions